Skip to main content
. Author manuscript; available in PMC: 2025 Dec 1.
Published in final edited form as: Biomaterials. 2024 Jun 27;311:122692. doi: 10.1016/j.biomaterials.2024.122692

Fig. 4.

Fig. 4.

Stability of bPACE-polyplexes transfection activity. (A-B) Differential EGFP expressions in A549 cells treated with EGFP/polyplexes stored at 37 °C for different time-points. (A) Percentages of EGFP expressed A549 cells transfected with polyplexes or lipofectamine MessengerMax (LipoMM) and (B) mean fluorescence intensities. (C-D) Stability of EGFP/bPACE polyplexes in serum-containing media. (C) Mean fluorescence intensity of EGFP signals from EGFP/polyplex-treated A549 cells depending on the incubation time in serum-containing media. (D) Percentage of EGFP-positive A549 cells treated with EGFP polyplexes, which was incubated in serum-containing media. (Polyplexes were formulated with 1:25 mRNA to polymer ratio (w/w), n=3, mean ± S.D.)